KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Gsk (GSK) Short term Debt (2016 - 2024)

Historic Short term Debt for Gsk (GSK) over the last 9 years, with Q4 2024 value amounting to $3.0 billion.

  • Gsk's Short term Debt fell 1364.55% to $3.0 billion in Q4 2024 from the same period last year, while for Dec 2024 it was $3.0 billion, marking a year-over-year decrease of 1364.55%. This contributed to the annual value of $3.0 billion for FY2024, which is 1418.19% down from last year.
  • As of Q4 2024, Gsk's Short term Debt stood at $3.0 billion, which was down 1364.55% from $3.5 billion recorded in Q4 2023.
  • In the past 5 years, Gsk's Short term Debt ranged from a high of $4.9 billion in Q4 2020 and a low of $3.0 billion during Q4 2024
  • For the 5-year period, Gsk's Short term Debt averaged around $4.2 billion, with its median value being $4.6 billion (2022).
  • Per our database at Business Quant, Gsk's Short term Debt tumbled by 4470.07% in 2020 and then crashed by 131.12% in 2021.
  • Quarter analysis of 5 years shows Gsk's Short term Debt stood at $4.9 billion in 2020, then dropped by 1.31% to $4.9 billion in 2021, then decreased by 4.51% to $4.6 billion in 2022, then dropped by 24.68% to $3.5 billion in 2023, then decreased by 13.65% to $3.0 billion in 2024.
  • Its last three reported values are $3.0 billion in Q4 2024, $3.5 billion for Q4 2023, and $4.6 billion during Q4 2022.